Since after the outbreak of COVID-19 happened in China, an increasingly more of confirmed cases and death cases have been reported. It is crucial to find a potential treatment for this epidemic. Based on the information provided by researchers, this virus is based on the RNA, cutting down the duplication of RNA can eventually inhibit the process of generating the protein, which is essential to the diffusion of virus. Fidaxomicin, a medicine that has a function to inhibit the polymerase in the process of transcription, which is one of those two processes of protein-generation. So, this medicine can theoretically inhibit the illness.
Keywords
Fidaxomicin; COVID-19; Protein-generation
The wide spread of novel coronavirus COVID-19 has caused increasingly worldwide intense of severity that more than 8000 people died and 217,787 confirmed as patient in total so far. It is really demanding for a kit of feasible treatments to inhibit the epidemic. The former scientists have already supposed several kinds of compounds that seem like effective, such as the Remdesivir, and Baricitinib[1].
The principal that how COVID-19 attacks human’s lung cells is that the virus firstly attaches the receptor on the plasma membrane as the start of endocytosis with the catalysis by the known regulators—AP2-associated protein kinase 1(AAK1), and cyclin G-associated kinase[1]. Disrupting these enzymes can decrease the efficiency of the endocytosis and spread of viruses. Within the cell, the COVID-19 depends on the RNA-Polymerase to replicate their RNA and generate the Protein that they require. Inhibiting the RNA-Polymerase can effectively disrupt the growth and spread of Virus, as their basic demands have been inhibited.
The Selleck[2], world leading producer of inhibitors, also owns one of the largest browsers for medical information in the world. We used Selleck to browse the proper compounds that can inhibit the RNA-Polymerase, and found that about 52 inhibitors have been approved for medical use. These include some drugs for Cancer and Oncology, which have serious side-effect on human body. Some of the 52 inhibitors are DNA-dependent RNA-Polymerase, which is not suitable for COVID-19(the suitable type of RNA-Polymerase should be RNA-Dependent RNA Polymerase). We don’t consider these drugs as feasible treatments.
By comparisons, one of the 52 RNA-Polymerase inhibitors is the RNA-dependent RNA Polymerase fidaxomicin[3], which has the ability to disrupt the process of transaction, eventually stop the protein production and the RNA-Replication(Appendix), which are the most basic pillars of virus. The normal side effects of this drug is the nausea, vomiting, headache, stomachache, and dysentery. Since the RNA Polymerase has been inhibited, the human body cannot spontaneously generate protein in some extent, so it is also necessary to supplement the extra amount of protein to the patient. We identified fidaxomicin, which is predicted to reduce the ability of the virus to replicate and generate protein.
Reference
1."Baricitinib as potential treatment for 2019-nCoV acute respiratory disease."?The Lancet. 4 Feb. 2020. Web. 19 Feb. 2020. <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/abstract>
2. N.a. "."?Selleck.cn. n.d. Web. 19 Feb. 2020. <https://www.selleck.cn/Anti-infection.html>
3. MCE-MedChemExpress.cn. "Fidaxomicin (OPT-80) | Bacterial 抑制剂 | MCE."?MCE-MedChemExpress.cn. n.d. Web. 19 Feb. 2020. <https://www.medchemexpress.cn/Fidaxomicin.html>
4. Aiping Wu. "Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China."?Cell Host & Microbe. 7 Feb. 2020. Web. 19 Feb. 2020. <https://www.cell.com/cell-host-microbe/abstract/S1931-3128(20)30072-X>
5. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."?The Lancet. 30 Jan. 2020. Web. 19 Feb. 2020. <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/abstract>
Appendix
.png)
Author
Xuanyu Meng, a student from Shen Wai International School, participated in the research program conducted by the Institution of Computing Technology, Chinese Academy of Science about how the Computer Science interprets the Mathematics, and has been granted as a Honor Student. He has issued an article on the Journal of Chinese Computing Technology about the Turing’s essay named “Computing Machinery and Intelligence”.
论文作者:Xuanyu Meng
论文发表刊物:《医师在线》2020年6期
论文发表时间:2020/4/21
标签：抑制剂论文; cyclin论文; enzymes论文; Disrupting论文; mdash论文; regulators论文; kinase论文; 《医师在线》2020年6期论文;